Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence specialty medicine areas.
Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence in specialty medicine areas.
The financial terms of the deal were not disclosed.
The 30-year-old company operates in a niche ophthalmic segment and owns about 50 trademarks and brands like Renicol, Dexacort, Lysicon-V, in eye care, Vivimed said Monday.
Klar Sehen has strong marketing presence in North East, Bihar and Andhra Pradesh, it said. It has manufacturing facilities at Kolkata and Hyderabad and also has arrangements to manufacture some of its products in Uttarakhand, and operates with over 150 medical sales professionals, Vivimed said.
Earlier last month Vivimed had completed the acquisition of Octtantis Nobel, a Hyderabad-based pharmaceutical marketing company.
Vivimed Labs shares were trading up 1.2% at Rs 247.50 on NSE on Monday.
Vivimed Labs stock price
On August 31, 2015, Vivimed Labs closed at Rs 275.80, up Rs 10.80, or 4.08 percent. The 52-week high of the share was Rs 435.40 and the 52-week low was Rs 175.00.
The company's trailing 12-month (TTM) EPS was at Rs 10.04 per share as per the quarter ended June 2015. The stock's price-to-earnings (P/E) ratio was 27.47. The latest book value of the company is Rs 240.91 per share. At current value, the price-to-book value of the company is 1.14.
Set email alert for
ADS BY GOOGLE
video of the day
Sensex can slip to 22K, FY16 GDP sliced to 6.8%: Ambit Cap